Please use this identifier to cite or link to this item: https://hdl.handle.net/1/234
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoger, Simon Den
dc.date.accessioned2015-04-22T23:39:05Zen
dc.date.available2015-04-22T23:39:05Zen
dc.date.issued2009-10en
dc.identifier.citationVolume 32, Number 5, pp. 129-131en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/234en
dc.description.abstractAnaemia is a common manifestation of chronic kidney disease, especially when the glomerular filtration rate falls below 30 mL/min. It is important to exclude other causes of anaemia such as iron and other haematinic deficiencies, chronic inflammation, malignancy and drugs. After reversible causes of anaemia are excluded, supplementary erythropoietin (epoetin) can be considered when the patient's haemoglobin concentration falls below 100 g/L. Patients treated with epoetin often require supplements of oral or intravenous iron to maintain adequate iron stores during the correction and the maintenance phases of management. The main adverse effect of epoetin use is the development or worsening of hypertension. Care must also be taken not to overshoot the target haemoglobin of 110–120 g/L, as this can be associated with a prothrombotic tendency.en
dc.subjectAnaemiaen
dc.subjectAnemiaen
dc.subjectKidney Diseaseen
dc.subjectHematologyen
dc.subjectHaematologyen
dc.titleManaging Anaemia of chronic kidney diseaseen
dc.typeJournal Articleen
dc.identifier.journaltitleAustralian Prescriberen
dc.originaltypeTexten
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Appears in Collections:Renal Medicine
Show simple item record

Page view(s)

48
checked on Nov 29, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.